Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 11;13(1):e03379-21. doi: 10.1128/mbio.03379-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.

PMC Copyright notice

FIG 2 — Histopathology and immunohistochemistry of NHP lungs. (A) Pulmonary lesions depicting typical coronavirus respiratory pathologies, including locally extensive regions of bronchointerstitial pneumonia and proteinaceous fluid accumulation in adjacent alveoli (magnification, ×40; H&E). (B) Disseminated immunopathology with prominent perivascular lymphocytic cuffing and multifocal involvement at terminal airways (magnification, ×40; H&E). (C) i.n. vaccination shows pulmonary pathology characterized by a combination of interstitial pneumonia and immunopathology (magnification, ×40; H&E). (D) Foci of interstitial pneumonia are characterized by prominent type II pneumocyte hyperplasia, leukocyte infiltration, expansion of alveolar septa, and accumulation of low numbers of macrophages, neutrophils, and proteinaceous fluid in alveolar spaces (magnification, ×200; H&E). (E) Terminal airways and medium- to small-caliber blood vessels are cuffed by moderate numbers of lymphocytes with scattered eosinophils (magnification, ×200; H&E). (F) Foci of interstitial pneumonia show pronounced type II pneumocyte hyperplasia, thickening of alveolar septa by an infiltration of leukocytes, and leukocyte spillover into adjacent alveolar spaces, with moderate numbers of alveolar eosinophils noted and multifocal fibrin mats filling alveolar spaces (magnification, ×200; H&E). (G) Low numbers of type I pneumocytes in regions lacking pathology are immunoreactive for SARS-CoV-2 antibody (magnification, ×200; immunohistochemistry [IHC]). (H) SARS-CoV-2-specific immunoreactivity was not observed in evaluated sections of the i.m. vaccinated group (magnification, ×200; IHC). (I) Low numbers of type I pneumocytes and alveolar macrophages are immunoreactive for SARS-CoV-2 in select foci of interstitial pneumonia (magnification, ×200; IHC).